Toll-like receptor signaling in primary immune deficiencies

Annals of the New York Academy of Sciences

Volumn 1356, Issue 1, 2015, Pages 1-21

  Maglione, Paul J ^a   Simchoni, Noa ^a   Cunningham Rundles, Charlotte ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Human immunology; Infection; Primary immune deficiency; Toll like receptors

Indexed keywords

ADENOSINE DEAMINASE; I KAPPA B KINASE GAMMA; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; I KAPPA B KINASE; IKBKG PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; B LYMPHOCYTE; CHRONIC GRANULOMATOUS DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; GENETIC DISORDER; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HUMAN; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INFECTION SENSITIVITY; INNATE IMMUNITY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; SIGNAL TRANSDUCTION; X LINKED AGAMMAGLOBULINEMIA; AGAMMAGLOBULINEMIA; ANIMAL; BACTERIAL INFECTION; DEFICIENCY; GENETICS; IMMUNOLOGY; SEVERE COMBINED IMMUNODEFICIENCY; X CHROMOSOME LINKED DISORDER;

ADENOSINE DEAMINASE; AGAMMAGLOBULINEMIA; ANIMALS; BACTERIAL INFECTIONS; GENETIC DISEASES, X-LINKED; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; I-KAPPA B KINASE; JOB SYNDROME; MYELOID DIFFERENTIATION FACTOR 88; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84949102766     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12763     Document Type: Article

References (192)

1. Kawai, T. & S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
2. Kawasaki, T. & T. Kawai. 2014. Toll-like receptor signaling pathways. Front. Immunol. 5: 461.
3. Schatz, D.G. & Y. Ji. 2011. Recombination centres and the orchestration of V(D)J recombination. Nat. Rev. Immunol. 11: 251-263.
4. Uehara, A. et al. 2007. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol. Immunol. 44: 3100-3111.
5. Pegu, A. et al. 2008. Human lymphatic endothelial cells express multiple functional TLRs. J. Immunol. 180: 3399-3405.
6. Schenten, D. & R. Medzhitov. 2011. The control of adaptive immune responses by the innate immune system. Adv. Immunol. 109: 87-124.
7. Wong, T. et al. 2013. Human primary immunodeficiencies causing defects in innate immunity. Curr. Opin. Allergy Clin. Immunol. 13: 607-613.
8. Janeway, C.A., Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1): 1-13.
9. Kono, H. & K.L. Rock. 2008. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8: 279-289.
10. Medzhitov, R. 2009. Damage control in host-pathogen interactions. Proc. Natl. Acad. Sci. U.S.A. 106: 15525-15526.
11. Jin, M.S. et al. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130: 1071-1082.
12. Shimizu, T., Y. Kida & K. Kuwano. 2005. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1, TLR2, and TLR6. J. Immunol. 175: 4641-4646.
13. Lien, E. et al. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274: 33419-33425.
14. Drage, M.G. et al. 2009. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell. Immunol. 258: 29-37.
15. Ozinsky, A. et al. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Nat. Acad. Sci. U.S.A. 97: 13766-13771.
16. Bieback, K. et al. 2002. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol. 76: 8729-8736.
17. Medzhitov, R., P. Preston-Hurlburt & C.A. Janeway, Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
18. Bulut, Y. et al. 2002. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J. Immunol. 168: 1435-1440.
19. Kurt-Jones, E.A. et al. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1: 398-401.
20. Tada, H. et al. 2002. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. Immunol. 46: 503-512.
21. Gewirtz, A.T. et al. 2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 167: 1882-1885.
22. Alexopoulou, L. et al. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
23. Diebold, S.S. et al. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
24. Heil, F. et al. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
25. Hemmi, H. et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
26. Lee, S.M. et al. 2014. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc. Nat. Acad. Sci. U.S.A. 111: 3793-3798.
27. Oosting, M. et al. 2014. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc. Nat. Acad. Sci. U.S.A. 111: E4478-E4484.
28. Yamamoto, M. et al. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643.
29. Yamamoto, M. et al. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. 4: 1144-1150.
30. Beutler, B. 2009. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol. Rev. 227: 248-263.
31. Ysebrant de Lendonck, L., V. Martinet & S. Goriely. 2014. Interferon regulatory factor 3 in adaptive immune responses. Cell. Mol. Life Sci. 71: 3873-3883.
32. Ning, S., J.S. Pagano & G.N. Barber. 2011. IRF7: activation, regulation, modification and function. Genes & Immunity 12: 399-414.
33. Shaulian, E. & M. Karin. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4: E131-E136.
34. vonBernuth, H. et al. 2012. Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans. Eur. J. Immunol. 42: 3126-3135.
35. Sun, S.C. 2012. The noncanonical NF-kappaB pathway. Immunol. Rev. 246: 125-140.
36. Frans, G. et al. 2014. Addressing diagnostic challenges in primary immunodeficiencies: laboratory evaluation of Toll-like receptor- and NF-kappaB-mediated immune responses. Crit. Rev. Clin. Lab. Sci. 51: 112-123.
37. Gardam, S. & R. Brink. 2014. Non-Canonical NF-kappaB Signaling Initiated by BAFF Influences B Cell Biology at Multiple Junctures. Front. Immunol. 4: 509.
38. Stepensky, P. et al. 2013. Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects. J. Allergy Clin. Immunol. 131: 477-485 e471.
39. Greil, J. et al. 2013. Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency. J. Allergy Clin. Immunol. 131: 1376-1383 e1373.
40. Jabara, H.H. et al. 2013. A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency. J. Allergy Clin. Immunol. 132: 151-158.
41. Picard, C. et al. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079.
42. vonBernuth, H. et al. 2008. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321: 691-696.
43. Yamamoto, M. et al. 2002. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420: 324-329.
44. Maglione, P.J. et al. 2014. IRAK-4- and MyD88- deficiencies impair IgM responses against T-independent bacterial antigens. Blood 124: 3561-3571.
45. Ku, C.L. et al. 2007. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 204: 2407-2422.
46. Picard, C. et al. 2010. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89: 403-425.
47. Picard, C., J.L. Casanova & A. Puel. 2011. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin. Microbiol. Rev. 24: 490-497.
48. Ku, C.L. et al. 2007. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44: 16-23.
49. Borgers, H. et al. 2010. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin. Immunol. 134: 198-205.
50. Cerutti, A., M. Cols & I. Puga. 2013. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat. Rev. Immunol. 13: 118-132.
51. + B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients. Blood 120: 4992-5001.
52. Weller, S. et al. 2004. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104: 3647-3654.
53. Martin, F., A.M. Oliver & J.F. Kearney. 2001. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14: 617-629.
54. Aucouturier, P. et al. 1988. [Serum levels of IgG subclasses in the normal child. Evaluation by an immunoenzymatic method using monoclonal antibodies]. Arch. Fr. Pediatr. 45: 255-258.
55. Douglas, R.M. et al. 1983. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148: 131-137.
56. Alsina, L. et al. 2014. A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4. Nat. Immunol. 15: 1134-1142.
57. Doffinger, R. et al. 2001. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 27: 277-285.
58. Courtois, G. et al. 2003. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112: 1108-1115.
59. Orange, J.S. et al. 2004. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J. Allergy Clin. Immunol. 113: 725-733.
60. Puel, A. et al. 2004. Inherited disorders of NF-kappaB-mediated immunity in man. Curr. Opin. Immunol. 16: 34-41.
61. Hanson, E.P. et al. 2008. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J. Allergy Clin. Immunol. 122: 1169-1177 e1116.
62. Orange, J.S. et al. 2004. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J. Allergy Clin. Immunol. 114: 650-656.
63. Niehues, T. et al. 2004. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J. Allergy Clin. Immunol. 114: 1456-1462.
64. Dai, Y.S. et al. 2004. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J. Am. Acad. Dermatol. 51: 718-722.
65. Filipe-Santos, O. et al. 2006. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J. Exp. Med. 203: 1745-1759.
66. Ku, C.L. et al. 2005. NEMO mutations in 2 unrelated boys with severe infections and conical teeth. Pediatrics 115: e615-e619.
67. Dupuis-Girod, S. et al. 2006. Successful allogeneic hemopoietic stem cell transplantation in a child who had anhidrotic ectodermal dysplasia with immunodeficiency. Pediatrics 118: e205-e211.
68. Tono, C. et al. 2007. Correction of immunodeficiency associated with NEMO mutation by umbilical cord blood transplantation using a reduced-intensity conditioning regimen. Bone Marrow Transplant. 39: 801-804.
69. Fish, J.D. et al. 2009. Challenges in the use of allogeneic hematopoietic SCT for ectodermal dysplasia with immune deficiency. Bone Marrow Transplant. 43: 217-221.
70. Permaul, P. et al. 2009. Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: case report and review of outcomes. Immunol. Res. 44: 89-98.
71. Abbott, J.K. et al. 2014. Successful hematopoietic cell transplantation in patients with unique NF-kappaB essential modulator (NEMO) mutations. Bone Marrow Transplant. 49: 1446-1447.
72. Mousallem, T. et al. 2014. A nonsense mutation in IKBKB causes combined immunodeficiency. Blood 124: 2046-2050.
73. He, B. et al. 2010. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat. Immunol. 11: 836-845.
74. Vincent, F.B. et al. 2013. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24: 203-215.
75. Zhang, L. et al. 2007. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J. Allergy Clin. Immunol. 120: 1178-1185.
76. Salzer, U. et al. 2009. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113: 1967-1976.
77. Martinez-Gallo, M. et al. 2013. TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes. J. Allergy Clin. Immunol. 131: 468-476.
78. Boisson, B. et al. 2012. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat. Immunol. 13: 1178-1186.
79. Zhang, S.Y. et al. 2007. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317: 1522-1527.
80. Casrouge, A. et al. 2006. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314: 308-312.
81. Perez de Diego, R. et al. 2010. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33: 400-411.
82. Sancho-Shimizu, V. et al. 2011. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121: 4889-4902.
83. Herman, M. et al. 2012. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 209: 1567-1582.
84. Guo, Y. et al. 2011. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208: 2083-2098.
85. Lafaille, F.G. et al. 2012. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 491: 769-773.
86. Medvedev, A.E. 2013. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer. J. Interferon Cytokine Res. 33: 467-484.
87. Netea, M.G., C. Wijmenga & L.A. O'Neill. 2012. Genetic variation in Toll-like receptors and disease susceptibility. Nat. Immunol. 13: 535-542.
88. Hawn, T.R. et al. 2009. Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. PLoS One 4: e8300.
89. Takahashi, M. et al. 2011. Toll-like receptor 2 gene polymorphisms associated with aggressive periodontitis in Japanese. Open Dent. J. 5: 190-194.
90. Emingil, G. et al. 2007. Toll-like receptor 2 and 4 gene polymorphisms in generalized aggressive periodontitis. J. Periodont. 78: 1968-1977.
91. Vuononvirta, J. et al. 2011. Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants. PLoS One 6: e26198.
92. Lee, S.O. et al. 2011. Toll-like receptor 2 polymorphism and Gram-positive bacterial infections after liver transplantation. Liver Transplant. 17: 1081-1088.
93. Kang, T.J. & G.T. Chae. 2001. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol. Med. Microbiol. 31: 53-58.
94. Kang, T.J., S.B. Lee & G.T. Chae. 2002. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 20: 56-62.
95. Bochud, P.Y., T.R. Hawn & A. Aderem. 2003. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170: 3451-3454.
96. Ben-Ali, M. et al. 2004. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients. Clin. Diagn. Lab. Immunol. 11: 625-626.
97. Ogus, A.C. et al. 2004. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur. Respir. J. 23: 219-223.
98. Xiong, Y. et al. 2012. R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88. J. Biol. Chem. 287: 38327-38337.
99. Kijpittayarit, S. et al. 2007. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin. Infect. Dis. 44: 1315-1320.
100. Kang, S.H. et al. 2012. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J. Infect. Dis. 205: 639-646.
101. Al-Qahtani, A. et al. 2012. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J. Med. Virol. 84: 1353-1359.
102. Sironi, M. et al. 2012. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J. Immunol. 188: 818-823.
103. Citores, M.J. et al. 2011. Toll-like receptor 3 L412F polymorphism may protect against acute graft rejection in adult patients undergoing liver transplantation for hepatitis C-related cirrhosis. Transplant. Proc. 43: 2224-2226.
104. Medhi, S. et al. 2011. Promoter region polymorphism & expression profile of toll like receptor-3 (TLR-3) gene in chronic hepatitis C virus (HCV) patients from India. Indian J. Med. Res. 134: 200-207.
105. Askar, E. et al. 2009. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. J. Med. Virol. 81: 1204-1211.
106. Svensson, A. et al. 2012. Polymorphisms in Toll-like receptor 3 confer natural resistance to human herpes simplex virus type 2 infection. J. Gen. Virol. 93: 1717-1724.
107. Agnese, D.M. et al. 2002. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 186: 1522-1525.
108. Lorenz, E. et al. 2002. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162: 1028-1032.
109. Tal, G. et al. 2004. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis. 189: 2057-2063.
110. Vander Graaf, C.A. et al. 2006. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur. Cytokine Netw. 17: 29-34.
111. Feterowski, C. et al. 2003. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 109: 426-431.
112. Nakada, T.A. et al. 2005. Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on clinical outcome in Japanese critically ill patients. J. Surg. Res. 129: 322-328.
113. Jessen, K.M. et al. 2007. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect. Dis. 7: 108.
114. Ferwerda, B. et al. 2007. The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania. Aids 21: 1375-1377.
115. Najmi, N. et al. 2010. Human Toll-like receptor 4 polymorphisms TLR4 Asp299Gly and Thr399Ile influence susceptibility and severity of pulmonary tuberculosis in the Asian Indian population. Tissue Antigens 76: 102-109.
116. Pulido, I. et al. 2010. The TLR4 ASP299GLY polymorphism is a risk factor for active tuberculosis in Caucasian HIV-infected patients. Curr. HIV Res. 8: 253-258.
117. Newport, M. J. et al. 2004. The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia. Tuberculosis 84: 347-352.
118. Xue, Y. et al. 2010. Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis. Int. J. Immunogenet. 37: 135-138.
119. Ragnarsdottir, B. et al. 2010. Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS One 5: e10734.
120. Hawn, T.R. et al. 2003. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J. Exp. Med. 198: 1563-1572.
121. Hawn, T.R. et al. 2009. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 4: e5990.
122. Schott, E. et al. 2008. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J. Viral Hepat. 15: 71-78.
123. Wang, C.H. et al. 2011. TLR7 and TLR8 gene variations and susceptibility to hepatitis C virus infection. PLoS One 6: e26235.
124. Al-Herz, W. et al. 2014. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front. Immunol. 5: 162.
125. Cunningham-Rundles, C. & C. Bodian. 1999. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92: 34-48.
126. Giovannetti, A. et al. 2007. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J. Immunol. 178: 3932-3943.
127. Viallard, J.F. et al. 2005. Altered dendritic cell distribution in patients with common variable immunodeficiency. Arthritis Res. Ther. 7: R1052-R1055.
128. Taraldsrud, E. et al. 2014. Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9. Clin. Exp. Immunol. 175: 439-448.
129. Barbosa, R.R. et al. 2012. Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. Clin. Exp. Immunol. 169: 263-272.
130. Branda, R.F. et al. 1996. B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin. Immunol. Immunopathol. 79: 115-121.
131. Du, X. et al. 2000. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. 11: 362-371.
132. Cunningham-Rundles, C. et al. 2006. TLR9 activation is defective in common variable immune deficiency. J. Immunol. 176: 1978-1987.
133. Escobar, D. et al. 2010. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus influenzae extracts in common variable immunodeficiency patients. Cell. Immunol. 262: 105-111.
134. Giordani, L. et al. 2009. IFN-alpha amplifies human naive B cell TLR9-mediated activation and Ig production. J. Leukoc. Biol. 86: 261-271.
135. Krug, A. et al. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31: 2154-2163.
136. Yu, J.E. et al. 2012. TLR-mediated B cell defects and IFN-α in common variable immunodeficiency. J. Clin. Immunol. 32: 50-60.
137. Sanchez-Ramon, S. et al. 2008. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin. Immunol. 128: 314-321.
138. Yu, J.E. et al. 2009. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J. Allergy Clin. Immunol. 124: 349-356, 356.e341-343.
139. Trujillo, C.M. et al. 2011. Quantitative and functional evaluation of innate immune responses in patients with common variable immunodeficiency. J. Investig. Allergol. Clin. Immunol. 21: 207-215.
140. Indrevær, R.L. et al. 2013. Retinoic acid improves defective TLR9/RP105-induced immune responses in common variable immunodeficiency-derived B cells. J. Immunol. 191: 3624-3633.
141. Coleman, M.M. et al. 2013. Alveolar macrophages contribute to respiratory tolerance by inducing FoxP3 expression in naive T cells. Am. J. Respir. Cell Mol. Biol. 48: 773-780.
142. + T cells and promote airway tolerance. J. Immunol. 191: 25-29.
143. Alimchandani, M. et al. 2013. Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients. Am. J. Surg. Pathol. 37: 1365-1372.
144. Hatanaka, E. et al. 2004. Hyperresponsiveness of neutrophils from gp 91phox deficient patients to lipopolysaccharide and serum amyloid A. Immunol. Lett. 94: 43-46.
145. Bylund, J. et al. 2007. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. Eur. J. Immunol. 37: 1087-1096.
146. Brown, K.L. et al. 2008. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin. Immunol. 129: 90-102.
147. Hartl, D. et al. 2008. Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease. J. Allergy Clin. Immunol. 121: 375-382.e379.
148. Cotugno, N. et al. 2015. Defective B-cell proliferation and maintenance of long-term memory in patients with chronic granulomatous disease. J. Allergy Clin. Immunol. 135: 753-761.e2
149. Moir, S. et al. 2012. Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells. Blood 120: 4850-4858.
150. Gelderman, K.A. et al. 2006. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc. Natl. Acad. Sci. U. S. A. 103: 12831-12836.
151. Hultqvist, M. et al. 2006. A new arthritis therapy with oxidative burst inducers. PLoS Med. 3: e348.
152. Bruton, O.C. 1952. Agammaglobulinemia. Pediatrics 9: 722-728.
153. Vetrie, D. et al. 1993. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361: 226-233.
154. deWeers, M. et al. 1994. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J. Biol. Chem. 269: 23857-23860.
155. Aoki, Y., K.J. Isselbacher & S. Pillai. 1994. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc. Natl. Acad. Sci. U. S. A. 91: 10606-10609.
156. Mukhopadhyay, S. et al. 1999. Delayed clearance of filarial infection and enhanced Th1 immunity due to modulation of macrophage APC functions in xid mice. J. Immunol. 163: 875-883.
157. Horwood, N.J. et al. 2003. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production. J. Exp. Med. 197: 1603-1611.
158. González-Serrano, M.E. et al. 2012. Increased pro-inflammatory cytokine production after lipopolysaccharide stimulation in patients with X-linked agammaglobulinemia. J. Clin. Immunol. 32: 967-974.
159. Horwood, N.J. et al. 2006. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J. Immunol. 176: 3635-3641.
160. Jefferies, C.A. et al. 2003. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J. Biol. Chem. 278: 26258-26264.
161. Marron, T.U. et al. 2012. Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines. J. Allergy Clin. Immunol. 129: 184-190.e181-184.
162. Sochorová, K. et al. 2007. Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood 109: 2553-2556.
163. Taneichi, H. et al. 2008. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin. Immunol. 126: 148-154.
164. Danks, L. et al. 2011. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J. Bone Miner. Res. 26: 182-192.
165. Gagliardi, M.C. et al. 2003. Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function. Clin. Exp. Immunol. 133: 115-122.
166. Lougaris, V. et al. 2014. Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. J. Allergy Clin. Immunol. 133: 1644-1650.e1644.
167. Pérez de Diego, R. et al. 2006. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes. J. Allergy Clin. Immunol. 117: 1462-1469.
168. Mansell, A. et al. 2006. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7: 148-155.
169. Saito, K. et al. 2003. BTK regulates PtdIns-4, 5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity 19: 669-678.
170. Troutman, T.D. et al. 2012. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc. Natl. Acad. Sci. U. S. A. 109: 273-278.
171. Marron, T.U. et al. 2010. TLR signaling and effector functions are intact in XLA neutrophils. Clin. Immunol. 137: 74-80.
172. Quartier, P. et al. 1999. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 134: 589-596.
173. Howard, V. et al. 2006. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin. Immunol. 118: 201-208.
174. Minegishi, Y. et al. 2007. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448: 1058-1062.
175. Renner, E.D. et al. 2005. No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome. J. Clin. Immunol. 25: 321-328.
176. Hawn, T.R. et al. 2005. Hyper-IgE syndrome is not associated with defects in several candidate toll-like receptor pathway genes. Hum. Immunol. 66: 842-847.
177. Yeganeh, M. et al. 2008. Toll-like receptor stimulation induces higher TNF-alpha secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome. Int Arch. Allergy Immunol. 146: 190-194.
178. Holland, S.M. et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl J. Med. 357: 1608-1619.
179. Takeda, K. et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
180. Wang, T. et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10: 48-54.
181. Lee, H. et al. 2011. STAT3: a target to enhance antitumor immune response. Curr. Top. Microbiol. Immunol. 344: 41-59.
182. Kwan, A. et al. 2014. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 312: 729-738.
183. Cohen, A. et al. 1978. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl. Acad. Sci. U. S. A. 75: 472-476.
184. Hershfield, M.S. & N.M. Krodich. 1978. S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. Science 202: 757-760.
185. VanDe Wiele, C.J. et al. 2002. Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J. Clin. Invest. 110: 395-402.
186. Hershfield, M.S. 1995. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum. Mutat. 5: 107-112.
187. Gaspar, H.B. et al. 2013. How I treat severe combined immunodeficiency. Blood 122: 3749-3758.
188. Sauer, A.V. et al. 2012. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J. Clin. Invest. 122: 2141-2152.
189. Minguet, S. et al. 2005. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur. J. Immunol. 35: 31-41.
190. Power Coombs, M.R. et al. 2011. Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev. Anti. Infect. Ther. 9: 261-269.
191. Conley, M.E. & J.L. Casanova. 2014. Discovery of single-gene inborn errors of immunity by next generation sequencing. Curr. Opin. Immunol. 30C: 17-23.
192. Milner, J.D. & S.M. Holland. 2013. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat. Rev. Immunol. 13: 635-648.